This information has been laundered through two different websites, and ultimately the journal article can be found here so you don’t have to play a game of telephone written by someone who has literally no qualifications to do so.
Approximately 75% of breast cancers are estrogen receptor alpha-positive (ERα+), and targeting ERα directly with ERα antagonists/degraders or indirectly with aromatase inhibitors is a successful therapeutic strategy. However, such treatments are rarely curative and development of resistance is universal. We recently reported ErSO, a compound that induces ERα-dependent cancer cell death through a mechanism distinct from clinically approved ERα drugs, via hyperactivation of the anticipatory unfolded protein response. ErSO has remarkable tumor-eradicative activity in multiple ERα+ tumor models. While ErSO has promise as a new drug, it has effects on ERα-negative (ERα−) cells in certain contexts. Herein, we construct modified versions of ErSO and identify variants with enhanced differential activity between ERα+ and ERα– cells. We report ErSO-DFP, a compound that maintains antitumor efficacy, has enhanced selectivity for ERα+ cancer cells, and is well tolerated in rodents. ErSO-DFP and related compounds represent an intriguing new class for the treatment of ERα+ cancers.
Approximately 75% of breast cancers are of a certain type.
We know of ways to target this type of cancer directly and indirectly.
However, these methods rarely fully cure the problem, and the patient eventually develops a resistance to these treatments, which makes continued use less effective.
We recently examined and reported on a drug which targets this common cancer type in a novel way and is remarkably effective.
However, that drug also interacts with non-cancerous cells in certain contexts, which ideally you want a cancer-targeting drug to avoid wherever possible.
We examine and report on a variant of this drug that is similarly effective but is less likely to target non-cancerous cells.
It is tolerated well in rodents, and this drug and related drugs are worth exploring for treating this cancer type.
This information has been laundered through two different websites, and ultimately the journal article can be found here so you don’t have to play a game of telephone written by someone who has literally no qualifications to do so.
Thanks for popping in the link! Wow, what a read. I hope it leads to better treatment.
The abstract from that linked page:
Not that I have any idea what that says…